Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
about
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyKey design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleThe changing landscape of biosimilars in rheumatologyBiosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis.Investigational drugs for treating psoriatic arthritis.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.Biosimilar monoclonal antibodies: the scientific basis for extrapolation.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Biosimilars in rheumatology: what the clinician should know.Differentiating biosimilarity and comparability in biotherapeutics.52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.Clinical trials of biosimilars should become more similar.Degree of prescriber's knowledge about variability in biological drugs "innovators" in manufacturing process.A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.[Biosimilars in rheumatology. Development and results of clinical trials].A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
P2860
Q26766028-B3277FEE-E875-4D71-AA29-B470865CB08BQ26766368-15EE3928-FC4F-4D34-B271-FB22372A49C1Q26766515-D2C836FF-F99C-4704-A6B1-FBA347AE8912Q30393052-44913148-866E-44F5-9E9C-9FDF4B742434Q33881234-C8D3BF48-A063-4BC6-8F63-FBACCA157C63Q37604531-31DC8FC6-08D8-43EC-81EF-D02B0D1C36DDQ38198090-2C3EEDEC-1E2E-4942-9E90-22CEDFF77DE8Q38206551-67CE9DE2-3008-40F9-B75A-A78C50370E2FQ38365041-E4776CD5-E63D-4ACD-887A-0B0D4861A3C9Q38586029-D305C13D-A328-4D2B-AB9E-61786B18A028Q38586044-C8022DFB-08C0-4EFD-A9F3-667E79357232Q38592363-88F7303A-F44E-48EE-80CE-711B500140E8Q38618144-343FA47F-7ADB-4993-9409-CEE2AC8EB15AQ38979267-2A0AAB6A-7D6D-4871-B971-590BB1BEDBBAQ47715028-178EDEF5-4C51-40E4-AACB-6E0CFB91E4C9Q47731175-4EB5A65C-B835-4A60-9062-3830B1CC8507Q48092147-42055D6E-1F02-475C-9F55-FD145FB6522AQ49788123-A9032979-6C1A-49C5-846C-0715EDD5E6B0Q50079741-C7E2D184-5082-4468-B990-261351E8E1A2Q52862599-DCB2CA8D-B6A5-428A-92EF-ED34A759C3EDQ53170870-00281DFC-8ED7-4CA3-B748-2548E234C677
P2860
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
@en
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
@nl
type
label
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
@en
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
@nl
prefLabel
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
@en
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
@nl
P2860
P1476
Biosimilars to treat inflammatory arthritis: the challenge of proving identity.
@en
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-203198
P407
P577
2013-07-29T00:00:00Z